Vaxon Biotech appoints CEO

01-Apr-2015 - France

Vaxon Biotech announces the appointment of company founder Dr. Konstantinos (Kostas) Kosmatopoulos, MD, PhD, as CEO. Kostas moves from his current role as chief scientific officer.  He will use his experience as a medical oncologist and immunologist to lead the company forward during a very active period.
 
Kostas established Vaxon Biotech in 2004 on the basis of his work as research director at Inserm, France’s national institute of health, and his work specializing in tumor immunotherapy at Institut Gustave Roussy (IGR). The two institutes granted Vaxon Biotech an exclusive worldwide license for three patents. The company subsequently filed seven more patents in its own name.
 
Kostas received his medical degree at the University of Thessaloniki, his medical oncology certification from Theagenion Cancer Research Institute, Greece, and his PhD in Immunology at Paris XI University, France. Dr. Kosmatopoulos has co-authored more than 50 scientific and international publications.

Other news from the department people

Most read news

More news from our other portals

Fighting cancer: latest developments and advances